FeldmanMD, CopelasL, GwathmeyJK, PhillipsP, WarrenSE, SchoenFJ, GrossmanW.Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation1987;75:331–9.
2.
GoldbergLI, HsiehY-Y, ResnekovL.Newer catecholamines for treatment of heart failure and shock: an update on dopamine and dobutamine. Prog Cardiovasc Dis1977;19:327–40.
ChatterjeeK.Newer oral inotropic agents: phosphodiesterase inhibitors. Crit Care Med1990;18:S34–8.
5.
WaagsteinF, BristowMR, SwedbergK, CameriniF, FowlerMB, SilverMA, GilbertEM, JohnsonMR, GossFG, HjalmarsonA.Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in dilated cardiomyopathy (MDC) trial study group. Lancet1993;342:1441–6
6.
PackerM, BristowMR, CohnJN, ColucciWS, FowlerMB, GilbertEM, ShustermanNH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. New Engl J Med1996;334:1349–55.
7.
BenovicJL, BouvierM, CaronMG, LefkowitzRJ. Regulation of adenylyl cyclase-coupled β-adrenergic receptors. Annu Rev Cell Biol1988; 4: 405–28.
8.
GoodmanAG. Nobel Lecture. G proteins and regulation of adenylyl cyclase. Biosci Rep1995;15: 65–97.
9.
IchikawaA, SugimotoY, NegishiM.Molecular aspects of the structures and functions of the prostaglandin E receptors. J Lipid Mediat Cell Signal1996;14:83–7.
10.
NegishiM, IrieA, SugimotoY, NambaT, IchikawaA.Selective coupling of prostaglandin E receptor EP3D to Gi and Gs through interaction of alpha-carboxylic acid of agonist and arginine residue of seventh transmembrane domain. J Biol Chem1995;270:16122–7.
11.
NegishiM, ItoS, HayaishiO.Prostaglandin E receptors in bovine adrenal medulla are coupled to adenylate cyclase via Gi and to phosphoinositide metabolism in a pertussis toxin-insensitive manner. J Biol Chem1989;264:3916–23.
12.
FreissmuthM, CaseyPJ, GilmanAG. G proteins control diverse pathways of transmembrane signaling. FASEB J1989;3:2125–31.
13.
HeplerJR, GilmanAG. G proteins. Trends Biochem Sci1992;17: 383–7.
14.
SpiegelAM. Signal transduction by guanine nucleotide binding proteins. Mol Cell Endocrinol1987;49:1–16.
15.
FreedmanNJ, LiggettSB, DrachmanDE, PeiG, CaronMG, LefkowitzRJ. Phosphorylation and desensitization of the human β1-adrenergic receptor. Involvement of G protein-coupled receptor kinases and cAMP-dependent protein kinase. J Biol Chem1995;270;17953–61.
16.
BenovicJL, PikeLJ, CerioneRA, StaniszewskiC, YoshimasaT, CodinaJ, CaronMG, LefkowitzRJ. Phosphorylation of the mammalian β-adrenergic receptor by cyclic AMP-dependent protein kinase. Regulation of the rate of receptor phosphorylation and dephosphorylation by agonist occupancy and effects on coupling of the receptor to the stimulatory guanine nucleotide regulatory protein. J Biol Chem1985;260:7094–101.
17.
BenovicJL, StrasserRH, CaronMG, LefkowitzRJ. B-adrenergic receptor kinase: identification of a novel protein kinase that phosphorylates the agonist-occupied form of the receptor. Proc Natl Acad Sci USA1986;83:2797–801.
18.
LohseMJ, BenovicJL, CodinaJ, CaronMG, LefkowitzRJ. B-arrestin: a protein that regulates B-adrenergic receptor function. Science1990;248:1547–50.
19.
LefkowitzRJ, IngleseJ, KochWJ, PitcherJ, AttramadalH; CaronMG. G-protein-coupled receptors: regulatory role of receptor kinases and arrestin proteins. Cold Spring Harb Symp Quant Biol1992;57:127–33.
20.
FergusonSS, DowneyWE 3rd, ColapietroAM, BarakLS, MenardL, CaronMG. Role of B-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science1996;271:363–6.
21.
PippigS, AndexingerS, LohseMJ. Sequestration and recycling of B2-adrenergic receptors permit receptor resensitization. Mol Pharmacol1995;47:666–76.
22.
YuSS, LefkowitzRJ, HausdorffWP. β-adrenergic receptor sequestration. A potential mechanism of receptor resensitization. J Biol Chem1993;268:337–41.
23.
FeldmanAM, CatesAE, VeazeyWB, HershbergerRE, BristowMR, BaughmanKL, BaumgartnerWA, Van DopC.Increase in the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest1988;82:189–97.
24.
BöhmM, GierschikP, JakobsKH, PieskeB, SchnabelP, UngererM, ErdmannE.Increase of Gαi in human heart with dilated but not ischemic cardiomyopathy. Circulation1990;82:1249–65.
25.
UngererM, BöhmM, ElceJS, ErdmannE, LohseMJ. Altered expression of β-adrenergic receptor kinase and β1-adrenergic receptors in the failing human heart. Circulation1993;87:454–63.
26.
BristowMR, GinsburgR, MinobeW, CubicciottiRS, SagemanWS, LurieK, BillinghamME, HarrisonDC, StinsonEB. Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts. N Engl J Med1982;307:205–11.
27.
BristowMR, GinsburgR, UmansV, FowlerM, MinobeW, RamussenR, ZeraP, MenloveR, ShahP, JamiesonS, StinsonEB. β1- and B2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective B1-receptor down-regulation in heart failure. Circ Res1986;59:297–309.
28.
BristowMR, HershbergerRE, PortJD, MinobeW, RasmussenR.B1 and B2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharm1989;35:295–303.
29.
MickeyJ, TateR, LefkowitzRJ. Subsensitivity of adenylate cyclase and decreased β-adrenergic receptor binding after chronic exposure to (-)-isoproterenol in vitro. J Biol Chem1975;250:5727–9.
30.
HomburgerV, LucasM, CantauB, BarabeJ, PenitJ, BockaertJ.Further evidence that desensitization of B-adrenergic sensitive adenylate cyclase proceeds in two steps. J Biol Chem1980;255:10436–44.
31.
LimasCJ, LimasC.Rapid recovery of cardiac β-adrenergic receptors after isoproterenol-induced downregulation. Circ Res1984;55:524–31.
32.
SigmundM, JakobH, BeckerH, HanrathP, SchumacherC, EschenhagenT, SchmitzW, ScholzH, SteinfathM.Effects of metoprolol on myocardial β-adrenoceptors and Gi alpha-proteins in patients with congestive heart failure. Eur J Clin Pharmacol1996;51:127–32.
33.
BristowMR, GinsburgR, StrosbergA, MontgomeryW, MinobeW.Pharmacology and inotropic potential of forskolin in the human heart. J Clin Invest1984;74:212–23.
34.
IyengarR.Molecular and functional diversity of mammalian Gs-stimulated adenylyl cyclases. FASEB J1993;7:768–75.
35.
SunaharaRK, DessauerCW, GilmanAG. Complexity and diversity of mammalian adenylyl cyclases. Annu Rev Pharmacol Toxicol1996;36:461–80.
HonerjägerP, Schafer-KortingM, ReiterM.Involvement of cyclic AMP in the direct inotropic action of amrinone: biochemical and functional evidence. Naunyn Schmiedebergs Arch Pharmacol1981;318:112–20.
40.
DageRC, RoebelLE, HsiehC-P, WeinerDL, WoodwardJK. Cardiovascular properties of a new cardiotonic agent MDL 17,043 (1,3 dihydro-4-methyl-5-[4-(methylthio)-benzoyl]-2H-imadazol-2-one). J Cardiovasc Pharmacol1982;4:500–8.
41.
RoebelLE, DageRC, ChengHC, WoodwardJK. In vitro and in vivo assessment of the cardiovascular effects of the cardiotonic drug MDL 19205. J Cardiovasc Pharmacol1984;6:43–9.
42.
BöhmM, DietF, FeilerG, KemkesB, KreuzerE, WeinholdC, ErdmannE.Subsensitivity of the failing human heart to isoprenaline and milrinone is related to β-adrenoceptor downregulation. J Cardiovasc Pharmacol1988;12:726–32.
43.
MovsesianMA, SmithCJ, KrallJ, BristowMR, ManganielloVC. Sarcoplasmic reticulum-associated cyclic adenosine 5’-monophosphate phosphodiesterase activity in normal and failing human hearts. J Clin Invest1991;88:15–9.
44.
GilbertEM, HershbergerRE, WiechmanRJ, MovsesianMA, BristowMR. Pharmacologic and hemodynamic effects of combined β-agonist stimulation and phosphodiesterase inhibition in the failing human heart. Chest1995;108:1524–32.
45.
BaimDS, McDowellAV, ChernilesJ, MonradES, ParkerJA, EdelsonJ, BraunwaldE, GrossmanW.Evaluation of a new bipyridine inotropic agent—milrinone—in patients with severe congestive heart failure. N Engl J Med1983;309:748–56.
46.
SinowayLS, MaskinCS, ChadwickB, FormanR, SonnenblickEH, LeJemtelTH. Long-term therapy with a new cardiotonic agent, WIN 47203: Drug-dependent improvement in cardiac performance and progression of the underlying disease. J Am Coll Cardiol1983;2:327–31.
47.
UretskyBF, GeneralovichT, ReddyPS, SpangenbergRB, FollansbeeWP. The acute hemodynamic effects of a new agent, MDL 17,043, in the treatment of congestive heart failure. Circulation1983;67:823–8.
48.
DiBiancoR, ShabetaiR, SilvermanBD, LeierCV, BenottiJR. Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study. J Am Coll Cardiol1984;4:855–66.
49.
JaskiBE, FiferMA, WrightRF, BraunwaldE, ColucciWS. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. J Clin Invest1985;75:643–9.
50.
MassieB, BourassaM, DiBiancoR, HessM, KonstamM, LikoffM, PackerM.Long- term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. Circulation1985;71:963–71.
51.
DiBiancoR, ShabetaiR, KostukW, MoranJ, SchlantRC, WrightR.A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med1989;320:677–83.
52.
UretskyBF, JessupM, KonstamMA, DecGW, LeierCV, BenottiJ, MuraliS, HerrmannHC, SandbergJA. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Circulation1990;82:774–80.
53.
NonyP, BoisselJ-P, LièvreM, LeizoroviczA, HaughMC, FarehS, de BreyneB.Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. Eur J Clin Pharmacol1994;46:191–6.
54.
HayesJS, BruntonLL, MayerSE. Selective activation of particulate cAMP-dependent protein kinase by isoproterenol and prostaglandin E. J Biol Chem1980;255:5113–9.
55.
BuxtonIL, BruntonLL. Compartments of cyclic AMP and protein kinase in mammalian cardiomyocytes. J Biol Chem1983;258:10233–9.
56.
XiaoRP, HohlC, AltschuldR, JonesL, LivingstonB, ZimanB, TantiniB, LakattaEG. B2-adrenergic receptor-stimulated increase in CAMP in rat heart cells is not coupled to changes in Ca2+ dynamics, contractility, or phospholamban phosphorylation. J Biol Chem1994;269:19151–6.
57.
YabanaH, SasakiY, NaritaH, NagaoT.Subcellular fractions of cyclic AMP and cyclic AMP-dependent protein kinase and the positive inotropic effects of selective B- and B2-adrenoceptor agonists in guinea pig hearts. J Cardiovasc Pharmacol1995;26:893–8.
58.
HohlCM, LiQ.Compartmentation of cAMP in adult canine ventricular myocytes. Relation to single-cell free Ca2+ transients. Circulation1991;69:1369–79.
59.
XiaoRP, LakattaEG. B1-adrenoceptor stimulation and β2-adrenoceptor stimulation differ in their effects on contraction, cytosolic Ca2+, and Ca2+ current in single rat ventricular cells. Circ Res1993;73:286–300.
60.
ExtonJH. Mechanisms of hormonal regulation of hepatic glucose metabolism. Diabetes Metab Rev1987;3:163–83.
61.
HabenerJF. Cyclic AMP response element binding proteins: a cornucopia of transcription factors. Mol Endocrinol1990;4:1087–94.
62.
BöhmM, ReigerB, SchwingerRHG, ErdmannE.cAMP concentrations, cAMP dependent protein kinase activity, and phospholamban in non-failing and failing myocardium. Cardiovasc Res1994;28:1713–9.
63.
SmithCJ, KrallJ, ManganielloVC, MovsesianMA. Cytosolic and sarcoplasmic reticulum-associated low Km, cGMP-inhibited cAMP phosphodiesterase in mammalian myocardium. Biochem Biophys Res Commun1993;190:516–21.
64.
TaylorSS, BuechlerJA, YonemotoW.CAMP-dependent protein kinase: framework for a diverse family of regulatory enzymes. Annu Rev Biochem1990;59:971–1005.
65.
ScottJD. Cyclic nucleotide-dependent protein kinases. Pharmacol Ther1991;50:123–45.
66.
JohnsonDA, LeathersVL, MartinezAM, WalshDA, FletcherWH. Fluorescence resonance energy transfer within a heterochromatic CAMP-dependent protein kinase holoenzyme under equilibrium conditions: new insights into the conformational changes that result in cAMP-dependent activation. Biochemistry1993;32: 6402–10.
67.
CorbinJD, SugdenPH, LincolnTM, KeelySL. Compartmentalization of adenosine 3':5'-monophosphate and adenosine 3':5'-monophosphate-dependent protein kinase in heart tissue. J Biol Chem1977;252:3854–61.
68.
LeiserM, RubinCS, ErlichmanJ.Differential binding of the regulatory subunits (RII) of cAMP-dependent protein kinase II from bovine brain and muscle to RII-binding proteins. J Biol Chem1986;261:1904–8.
69.
CoghlanVM, BergesonSE, LangebergL, NilaverG, ScottJD. A-Kinase anchoring proteins: a key to selective activation of CAMP-responsive events?Mol Cell Biochem1993;127/128:309–19.
70.
RobinsonML, WallertMA, ReinitzCA, ShabbJB. Association of the type I regulatory subunit of cAMP-dependent protein kinase with cardiac myocyte sarcolemma. Arch Biochem Biophys1996;330:181–7.
71.
OgreidD, EkangerR, SuvaRH, MillerJP, DøskelandSO. Comparison of the two classes of binding sites (A and B) of type I and type II cyclic-AMP-dependent protein kinases by using cyclic nucleotide analogs. Eur J Biochem1989;181:19–31.
72.
DostmannWRG, TaylorSS, GenieserH-G, JastorffB, DøskelandSO, OgreidD.Probing the cyclic nucleotide binding sites of CAMP-dependent protein kinases I and II with analogs of adenosine 3',5'-cyclic phosphorothioates. J Biol Chem1990;265:10484–91.
73.
GjertsenBT, MellgrenG, OttenA, MarondeE, GenieserHG, JastorffB, VintermyrOK, McKnightGS, DøskelandSO. Novel (Rp)-CAMPS analogs as tools for inhibition of cAMP-kinase in cell culture. J Biol Chem1995;270: 20599–607.
74.
SkålheggBS, LandmarkBF, DøskelandSO, HanssonV, LeaT, JahnsenT.Cyclic AMP-dependent protein kinase type I mediates the inhibitory effects of 3',5'-cyclic adenosine monophosphate on cell replication in human T lymphocytes. J Biol Chem1992;267:15707–14.
75.
LaxminarayanaD, BerradaA, KammerGM. Early events of human T lymphocyte activation are associated with type I protein kinase A activity. J Clin Invest1993;92: 2207–14.
76.
SculptoreanuA, RotmanE, TakahashiM, ScheuerT, CatterallWA. Voltage-dependent potentiation of the activity of cardiac L-type calcium channel alpha 1 subunits due to phosphorylation by cAMP-dependent protein kinase. Proc Natl Acad Sci USA1993;90:10135–9.
77.
De JonghKS, MurphyBJ, ColvinAA, HellJW, TakahashiM, CatterallWA. Specific phosphorylation of a site in the full-length form of the alpha 1 subunit of the cardiac L-type calcium channel by adenosine 3',5'-cyclic monophosphate-dependent protein kinase. Biochemistry1996;35:10392–402
78.
WitcherDR, KovacsRJ, SchulmanH, CefaliDC, JonesLR. Unique phosphorylation site on the cardiac ryanodine receptor regulates calcium channel activity. J Biol Chem1991;266:11144–52.
79.
HainJ, OnoueH, MayrleitnerM, FleischerS, SchindlerH.Phosphorylation modulates the function of the calcium release channel of sarcoplasmic reticulum from cardiac muscle. J Biol Chem1995;270:2074–81.
80.
SolaroRJ, RobertsonSP, JohnsonJD, HolroydeMJ, PotterJD. Troponin-I phosphorylation: a unique regulator of the amount of calcium required to activate cardiac myofibrils. Cold Spring Harb Conf Cell Proliferation1981;8:901–11.
81.
InuiM, ChamberlainBK, SaitoA, FleischerS.The nature of the modulation of Ca2+ transport as studied by reconstitution of cardiac sarcoplasmic reticulum. J Biol Chem1986;261:1794–1800.
82.
JamesP, InuiM, TadaM, ChiesiM, CarafoliE.Nature and site of phospholamban regulation of the Ca2+ pump of the sarcoplasmic reticulum. Nature1989;342:90–2.
83.
SasakiT, InuiM, KimuraY, KuzuyaT, TadaM.Molecular mechanism of regulation of Ca2+ pump ATPase by phospholamban in cardiac sarcoplasmic reticulum. Effects of synthetic phospholamban peptides on Ca2+ pump ATPase. J Biol Chem1992;267:1674–9.
84.
LuoW, GruppIL, HarrerJ, PonniahS, GruppG, DufyJJ, DoetschmanT, KraniasEG. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of β-agonist stimulation. Circ Res1994;75:401–9.
85.
LimasCJ, OlivariM-T, GoldenbergIF, LevineTB, BendittDG, SimonA.Calcium uptake by cardiac sarcoplasmic reticulum in human dilated cardiomyopathy. Cardiovasc Res1987;21:601–5.
86.
HasenfussG, ReineckeH, StuderR, MeyerM, PieskeB, HoltzJ, HolubarschC, PosivalH, JustH, DrexlerH.Relation between myocardial function and expression of sarcoplasmic reticulum Ca2+-ATPase in failing and nonfailing human myocardium. Circ Res1994;75:434–42.
87.
SchwingerRHG, BöhmM, SchmidtU, KarczewskiP, BavendiekU, FleschM, KrauseEG, ErdmannE.Unchanged protein levels of SERCA II and phospholamban but reduced Ca2+ uptake and Ca2+-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulation1995;92:3220–8.
88.
FleschM, SchwingerRH, SchnabelP, SchifferF, van GelderI, BavendiekU, SudkampM, Kuhn-RegnierF, BöhmM.Sarcoplasmic reticulum Ca2+ATPase and phospholamban mRNA and protein levels in end-stage heart failure due to ischemic or dilated cardiomyopathy. J Mol Med1996;74: 321–32.
89.
StuderR, ReineckeH, BilgerJ, EschenhagenT, BöhmM, HasenfußG, JustH, HoltzJ, DrexlerH.Gene expression of the cardiac Na+-Ca2+ exchanger in end-stage human heart failure. Circ Res1994;75:443–53.
90.
MeyerM, SchillingerW, PieskeB, HolubarschC, HeilmannC, PosivalH, KuwajimaG, MikoshibaK, JustH, HasenfussG.Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation1995;92:778–84.
91.
MovsesianMA, ColyerJ, WangJH, KrallJ.Phospholamban-mediated stimulation of Ca2+ uptake in sarcoplasmic reticulum from normal and failing hearts. J Clin Invest1990;85:1698–702.
92.
LinckB, BoknikP, EschenhagenT, MüllerFU, NeumannJ, NoseM, JonesLR, SchmitzW, ScholzH.Messenger RNA expression and immunological quantification of phospholamban and SR Ca2+-ATPase in failing and nonfailing human hearts. Cardiovasc Res1996;31: 625–32.
93.
MovsesianMA, SmithCJ, KrallJ, BristowMR, ManganielloVC. Sarcoplasmic reticulum-associated cyclic adenosine 5’-monophosphate phosphodiesterase activity in normal and failing human hearts. J Clin Invest1991;88:15–9.
94.
MovsesianMA, KarimiM, GreenK, JonesLR. Ca2+-transporting ATPase, phospholamban and calsequestrin levels in nonfailing and failing human myocardium. Circulation1994;90:653–7.
95.
NimerLR, NeedlemanDH, HamiltonSL, KrallJ, MovsesianMA. Effect of ryanodine on sarcoplasmic reticulum Ca2+ accumulation in nonfailing and failing human myocardium. Circulation1995;92:2504–10.
96.
SchwingerRHG, BavendieckU, BölckB, HörterS, HoischenS, BrixiusK, KarzcewskiP, KrauseEG, ErdmannE.Phosphorylation of phospholamban influences Ca2+-sensitivity but not maximal Ca2+-ATPase activity of SERCA II in human myocardium (abstract]. Circulation1996;94:I-673.
